Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00449670
Status:
COMPLETED
Last Update Posted:
2020-04-09
First Post:
2007-03-19
Brief Title:
Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals Pandemic Influenza Vaccine GSK1562902A in Adults
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Assess the Consistency of the Immunogenicity of a GlaxoSmithKline Biologicals Pandemic Influenza Vaccine GSK1562902A in Adults Aged Between 18 and 60 Years
Status:
COMPLETED
Status Verified Date:
2020-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The present study is designed to assess the lot-to-lot consistency of the immunogenicity of a GlaxoSmithKline Biologicals pandemic influenza candidate vaccine GSK1562902A in adults aged between 18 and 60 years
Detailed Description:
The protocol posting has been updated to reflect changes due to an amendment to the protocol addition of an exclusion criterion The Protocol Posting has been updated in order to comply with the FDA Amendment Act Sep 2007
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 109873 | OTHER | GSK | None |